Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN727 versus ezetimibe in statin-intolerant primary hypercholesterolemia
2012-001221-27Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia and familial hypercholesterolemia (FH) (2 arms), sponsored by Regeneron Pharmaceuticals. Started Dec 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2012-001221-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001221-27.